PMID- 22405734
OWN - NLM
STAT- MEDLINE
DCOM- 20130206
LR  - 20220331
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 84
IP  - 1
DP  - 2012 Oct
TI  - Multitargeted anti-angiogenic agents and NSCLC: clinical update and future 
      directions.
PG  - 47-58
LID - S1040-8428(12)00043-1 [pii]
LID - 10.1016/j.critrevonc.2012.02.004 [doi]
AB  - Increasing understanding of the molecular abnormalities driving cell growth and 
      proliferation has resulted in extensive research into molecularly targeted 
      therapies. Angiogenesis is an appealing target for the treatment of non small 
      cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody against circulating 
      vascular endothelial growth factor (VEGF), is already approved for the treatment 
      of NSCLC. Many other anti-angiogenic agents under development form the focus of 
      this review. A variety of agents, including sorafenib, sunitinib, cediranib, 
      axitinib, motesanib, linifinib and brivanib inhibit VEGF in addition to either 
      platelet derived growth factor (PDGF), or fibroblast derived growth factor (FGF). 
      To date, none of these agents in combination with chemotherapy have resulted in 
      improvements in overall survival for patients with advanced NSCLC. Triple 
      angiokinase inhibitors, which inhibit VEGF, PDGF and FGF, have potential to 
      improve the therapeutic outcomes for patients with NSCLC. However, there is a 
      need for identification of appropriate biomarkers to improve patient selection 
      and identify those patients benefiting from anti-angiogenesis therapy.
CI  - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Ellis, Peter M
AU  - Ellis PM
AD  - Juravinski Cancer Centre, Hamilton, Ontario, Canada. peter.ellis@jcc.hhsc.ca
FAU - Al-Saleh, Khalid
AU  - Al-Saleh K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120308
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism
MH  - Enzyme Inhibitors/pharmacology/therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Receptors, Platelet-Derived Growth Factor/antagonists & inhibitors
MH  - Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
MH  - Signal Transduction/drug effects
EDAT- 2012/03/13 06:00
MHDA- 2013/02/07 06:00
CRDT- 2012/03/13 06:00
PHST- 2011/09/15 00:00 [received]
PHST- 2012/01/31 00:00 [revised]
PHST- 2012/02/08 00:00 [accepted]
PHST- 2012/03/13 06:00 [entrez]
PHST- 2012/03/13 06:00 [pubmed]
PHST- 2013/02/07 06:00 [medline]
AID - S1040-8428(12)00043-1 [pii]
AID - 10.1016/j.critrevonc.2012.02.004 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. doi: 
      10.1016/j.critrevonc.2012.02.004. Epub 2012 Mar 8.